News

Immuneering stock soars on clinical supply deal with Eli Lilly

Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced ...
Stocktwits on MSN11h

Immuneering Inks Supply Agreement With Eli Lilly For Latter’s Investigational Cancer Therapy: Retail Looks To Buy The Stock On Dips

Immuneering Corporation (IMRX) on Monday announced a clinical supply agreement with Eli Lilly and Company (LLY) for the ...

Immuneering Shares Climb On Supply Agreement with Eli Lilly

Shares of Immuneering rose after the company entered into a clinical supply agreement for Eli Lilly's olomorasib drug to support testing of Immuneering's proposed lung-cancer treatment. The stock was ...

Immuneering signs supply deal with Lilly to test atebimetinib plus olomorasib

Immuneering (IMRX) partners with Eli Lilly to test atebimetinib + olomorasib in a phase 2 trial targeting KRAS G12c-mutant ...
The Manila Times15h

Beyond Oil Announces Conditional Approval of Uplisting to the Toronto Stock Exchange

VANCOUVER, British Columbia and KIBBUTZ YIFAT, Israel, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (CSE:BOIL) (OTCQB:BEOLF) ('Beyond Oil” or the 'Company”), a food-tech innovation company ...

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ...
InvestorsHub on MSN4d

Immuneering Secures $25 Million in Private Placement to Advance Cancer Drug Development

Immuneering Corporation (NASDAQ:IMRX), a clinical-stage biotechnology company specializing in oncology treatments, announced ...

Immuneering Shares Gain on $25 Million Private Placement

Immuneering said investors agreed to buy roughly 6.3 million shares of its Class A common stock for $3.95 a piece. In lieu of Class A common stock, certain investors will buy pre-funded warrants to ...

Immuneering Announces $25 Million Private Placement

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it has entered into a definitive securities purchase agreement ...
manilatimes5d

Freight Technologies Announces Second Quarter 2025 Results

HOUSTON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Freight Technologies, Inc. (Nasdaq: FRGT; "Fr8Tech” or the "Company”), a logistics ...

Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates

Company now plans to share updated OS and PFS data from first-line pancreatic cancer patients (N = 34) treated with atebimetinib + mGnP in Q3 2025, earlier than prior guidance - - Exceptional 94% ...
Wane2mon

Immuneering Reports Positive Overall Survival Data for Atebimetinib ...

CAMBRIDGE, Mass., June 17, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company outpacing cancer to help patients outlive their disease, today ...